Cardiac Performance in Pregnant Obese Women:Are They in Jeopardy?

July 10, 2018 updated by: ahmed abdulmoneim altraigey, Benha University
The aim of this work is to Assess serial changes in "cardiovascular function" in morbidly obese pregnant females (BMI equal or higher than 30 kg/m2) as compared to normal lean pregnant female controls.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Overweight and obesity are defined as: abnormal or, excessive fat accumulation that presents a risk to health. A crude population measure of obesity is the body mass index (BMI), a person's weight (in kilograms) divided by the square of his or her height (in meters). A person with a BMI of 30 or more is generally considered obese. A person with a BMI equal to or more than 25 is considered overweight.

Obesity has reached particularly alarming levels in the Middle East and North Africa (MENA) region. The prevalence of female obesity currently estimated at over 40% , had already exceeded that in Europe and the USA.

Obesity has been linked to several major chronic diseases, including type II diabetes, cardiovascular diseases, selected cancers, gallbladder disease, asthma, osteoarthritis, and chronic back pain.

Obesity has been also linked to a wide spectrum of cardiovascular changes ranging from a hyper dynamic circulation, through subclinical cardiac structural changes, to overt heart failure.

Obesity is associated with hemodynamic overload due to the increased metabolic demand imposed by the expanded adipose tissue and augmented fat-free mass in obesity results in a hyper dynamic circulation with increased blood volume. In addition to the increased preload, left ventricular (LV) after load is also elevated in obese individuals due to both increased peripheral resistance and greater conduit artery stiffness. Right ventricular after load may be increased, presumably due to associated sleep disordered breathing and LV changes.

Pregnancy is associated with hemodynamic and hormonal changes that can affect the heart. From the first trimester, there is an increase in cardiac output that places a volume load on the heart. Hormonal changes include increased circulating estrogen and relaxin, which may directly or indirectly affect the heart. During pregnancy, the heart undergoes remodeling similar to that observed in athletes, with increases in chamber dimensions, left ventricular (LV) wall thickness, and mass, that is consistent with a process of eccentric hypertrophy.

Myocardial contractile function also changes in pregnancy. Ejection-phase indices of LV function, including systolic fractional shortening (FS) and mean velocity of circumferential fiber thickening (V CFC), have been variously reported to increase, remain constant,or decrease, during pregnancy. Thus, obese women are more likely to encounter problems on becoming pregnant.

There is large evidence in the literature demonstrating that women who are overweight are at greater risk of developing pregnancy complications and problems associated with labor and delivery.

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Asir,
      • Khamis Mushait,, Asir,, Saudi Arabia, 101
        • antenatal clinic of Armed Forces Hospital, Southern Region

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Any pregnant woman in her 1st trimester with a singleton live healthy pregnancy will be eligible for inclusion in the study. Eligible women will be further categorized into case and control groups. Women with body mass index equals or more than 30kg/m2 will be considered case. Control women will be with BMI equals or less than 25 kg/m2.

Description

Inclusion Criteria:

  • Any pregnant woman in her 1st trimester with a singleton live healthy pregnancy

Exclusion Criteria:

  • Multiple gestations.
  • Anemia.
  • Medical history of hypertension.
  • Medical history of any cardiac disease.
  • Medical history of pre-gestational diabetes.
  • Development of gestational diabetes and pre-eclampsia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
obese pregnant women

pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.

Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation.

At each echocardiographic evaluation, the investigator will obtain the following parameters:

Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume

lean pregnant women

pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.

Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation.

At each echocardiographic evaluation, the investigator will obtain the following parameters:

Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cardiac performance
Time Frame: 2 hours
the cardiac performance (the left ventricular functions) in obese and lean pregnant women throughout each trimester and six weeks postpartum.
2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prevalence of cardiac lesions.
Time Frame: 2 hours
the presence of other unnoticed cardiac lesions among candidates
2 hours
The need of any medications among obese pregnant women
Time Frame: 9 months
if an echo cardiogram results necessitate prescribing medication for any obese pregnant woman
9 months
The need of any advanced investigation among obese pregnant women
Time Frame: 9 months
if an echo cardiogram results necessitate initiating advanced investigation for any obese pregnant woman
9 months
The need of hospitalization among obese pregnant women
Time Frame: 9 months
if an echo cardiogram results necessitate hospitalization for any obese pregnant woman
9 months
The need of termination of pregnancy among obese pregnant women
Time Frame: 9 months
if an echo cardiogram results necessitate termination of pregnancy for any obese pregnant woman
9 months
Maternal pregnancy outcomes
Time Frame: 9 months
weight gain, obstetric disorders type delivery, duration of childbirth, blood pressure evolution, postpartum complications
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: haytham attya, Zagazig University
  • Principal Investigator: mohammed mesilhy, Armed Forces Hospitals, Southern Region, Saudi Arabia
  • Principal Investigator: mohammed attia, Armed Forces Hospitals, Southern Region, Saudi Arabia
  • Principal Investigator: mohammed shehri, Armed Forces Hospitals, Southern Region, Saudi Arabia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2015

Primary Completion (Actual)

August 1, 2017

Study Completion (Actual)

August 1, 2017

Study Registration Dates

First Submitted

May 2, 2015

First Submitted That Met QC Criteria

May 5, 2015

First Posted (Estimate)

May 6, 2015

Study Record Updates

Last Update Posted (Actual)

July 11, 2018

Last Update Submitted That Met QC Criteria

July 10, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • AFHSRMREC/2015/OB/GYNAE/061

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Performance

Clinical Trials on echocardiogram

3
Subscribe